StockTipsArenaBeta

BUY Jubilant Pharmova Limited — Gaurav Sharma

BUYJubilant Pharmova Limited

byGaurav SharmaHorizon: NA (inferred Swing (≤2wk))14 May 2026via CNBC Awaaz.

Entry₹1,012Stated
Target₹1,075
Total upside +6.23% (call closed)
Stop loss₹975-3.66% risk
Exit₹97525 May 2026, 9:20 am
Stop-loss hit-3.66%
Follow Gaurav Sharma for new calls(28% target hit, 89 closed calls)Get alertsWatch JUBLPHARMA for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 5:42 am IST
2 supporting2 neutral0 opposing
Supports the BUY call (2)

Jubilant Pharmova Limited announced the appointment of Mr. Priyavrat Bhartia as Managing Director, effective June 1, 2026.

NSE · Appointment·22 May · 2d ago

(opens in new tab)

Mr. Ashish Mukkirwar has been appointed as the Chief Financial Officer of the company, effective May 23, 2026.

NSE · Appointment·22 May · 2d ago

(opens in new tab)
Neutral / worth noting (2)

Jubilant Generics Limited, a subsidiary of Jubilant Pharmova, received an order from the Income-tax department for tax adjustments of Rs. 107.89 crores. The company believes the adjustments ignore fac

NSE · Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company·22 May · 2d ago

(opens in new tab)

Jubilant Pharmova Limited's Board of Directors approved the audited financial results for the quarter and financial year ended March 31, 2026. The Board also recommended a final dividend of Rs. 5 per

NSE · Outcome of Board Meeting·22 May · 2d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.